

BEST OF SABCS CROATIA, Zagreb 16. - 17. February 2024.

PROGRAMME

FRIDAY, 16.2.2024.

15:00 Welcome and Introductions

15:10 – 16:30 Section 1.

Moderator: Marijana Jazvić

- J. JOVIĆ-ZLATOVIĆ:** Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients interrupting endocrine therapy (ET) to attempt pregnancy (POSITIVE trial)
- N. DEDIĆ PLAVETIĆ:** Biology or stage or menopausal status? What factors affect treatment choices in premenopausal women with HR+, node positive breast cancer?
- S. PLEŠTINA:** Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial
- T. SILOVSKI:** HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
- P. PODOLSKI:** Phase 3 study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2 positive early breast cancer after neoadjuvant chemotherapy and HER2 targeted therapy: KATHERINE final IDFS and updated OS analysis

A. BUDISAVLJEVIĆ: Phase 3 study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA mutant, HR pos HER2 neg locally advanced or metastatic breast cancer: INAVO120 primary analysis

A. STRIKIĆ: MONARCH-3. Final overall survival results of abemaciclib plus AI as first line therapy for ER+HER2 – advanced breast cancer

The satellite symposium section is not a part of the official program
of the Best of SABCS.

16:30 - 17:00

Satellite Symposium: AstraZeneca

17:00 – 17:20 Coffee break

The satellite symposium section is not a part of the official program
of the Best of SABCS.

17:20 – 17:50

Satellite Symposium: Novartis

17:50 – 18:50 Section 2. SURGERY

Moderator: Davor Mijatović

A. DUJMOVIĆ: Demystifying the Axilla: Challenging scenarios in upfront surgery setting and after NAC

N. FUCHS: Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.

CLINICAL CONTROVERSIES: *Are we ready to stop staging axilla?*

Rado ŽIC: YES

Ivan MILAS: NO

19:00 End of program

SATURDAY, 17.2.2024.

9:00 – 10:45: Section 3.

Moderator: Martina Bašić Koretić

S. BORŠTNAR: State -of -the- Art in Immunotherapy in breast cancer

M. BAN: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early stage high risk ER+/HER2-breast cancer; KEYNOTE-756

I. BELAC LOVASIĆ: Recent advanced in Triple negative Breast Cancer

B. PETRIĆ MIŠE: How to treat small triple negative Breast cancer: can we get it just right?

Ž. VOJNOVIĆ: Ribociclib+NSAI as adjuvant treatment in patients with HR+/HER2-early breast cancer: final iDFS analysis from NATALEE study

M. MILKOVIĆ PERIŠA: Is inflammatory breast cancer genomically different type of breast cancer

The satellite symposium section is not a part of the official program
of the Best of SABCS.

10:45 – 11:45

Satellite Symposium: Eli Lilly

11:45 – 12:05 Coffee break

12:05 – 12:50 Section 4. DEBATE

Moderator: Željko Soldić

DEBATE: *Anthracycline To give or not to give?*

M. JAZVIĆ: „For“ argument

LJ. VAZDAR: „Against“ argument

The satellite symposium section is not a part of the official program
of the Best of SABCS.

12: 50 – 13:10

Satellite Symposium Roche

The satellite symposium section is not a part of the official program
of the Best of SABCS.

13:10 - 13:30 **Satellite Symposium Pfizer**

13:30 – 14:30 **Lunch/Break**

The satellite symposium section is not a part of the official program
of the Best of SABCS.

14:30 – 15:00 **Satellite Symposium MSD**

15:00 – 16:15 **Section 5.**

Moderator: Paula Podolski

- M. PRUTKI:** Mammographic surveillance in early breast cancer patients aged 50 years or over: results of Mammo-50 non-inferiority trial of annual versus less frequent mammography
- M. ŠEKERIJA:** Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study

J. FLAM: Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50 - 69 with genomically-selected favorable Stage I breast cancer

N. ŠARIĆ: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B51/RTOG 130

M. SOČE: When less is more: Patient - friendly radiation courses with WBI and PBI

16:15 – 16:35 Coffee break

16:35 – 17:35 Section 6. YEAR IN THE REVIEW

Moderator: Eduard Vrdoljak

S. TOMIĆ: Translational

M. BAŠIĆ KORETIĆ: Early breast cancer

E. VRDOLJAK: Advanced breast cancer

17:35 – 17:50 WHAT WILL WE DO ON MONDAY MORNING?

17:50 Summary and Closing Remarks

18:00 End of the Symposium